| __timestamp | Novavax, Inc. | Protagonist Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 79435000 | 7459000 |
| Thursday, January 1, 2015 | 162644000 | 11831000 |
| Friday, January 1, 2016 | 237939000 | 25705000 |
| Sunday, January 1, 2017 | 168435000 | 46181000 |
| Monday, January 1, 2018 | 173797000 | 59497000 |
| Tuesday, January 1, 2019 | 113842000 | 65003000 |
| Wednesday, January 1, 2020 | 747027000 | 74506000 |
| Friday, January 1, 2021 | 2534508000 | 126006000 |
| Saturday, January 1, 2022 | 1235278000 | 126215000 |
| Sunday, January 1, 2023 | 737502000 | 120161000 |
Unlocking the unknown
In the ever-evolving world of biotechnology, research and development (R&D) investments are the lifeblood of innovation. Over the past decade, Protagonist Therapeutics, Inc. and Novavax, Inc. have demonstrated contrasting yet fascinating trajectories in their R&D expenditures. From 2014 to 2023, Novavax's R&D spending surged by over 900%, peaking in 2021 with a staggering 2.5 billion dollars, driven by their pivotal role in vaccine development. In contrast, Protagonist Therapeutics, while maintaining a steady growth, increased their R&D investments by approximately 1,500%, reaching their highest in 2022. This comparison not only highlights the dynamic nature of biotech investments but also underscores the strategic priorities of these companies. As the industry continues to innovate, understanding these financial commitments offers a glimpse into the future of medical breakthroughs.
Comparing Innovation Spending: Gilead Sciences, Inc. and Novavax, Inc.
Research and Development: Comparing Key Metrics for argenx SE and Protagonist Therapeutics, Inc.
R&D Insights: How Teva Pharmaceutical Industries Limited and Protagonist Therapeutics, Inc. Allocate Funds
Teva Pharmaceutical Industries Limited vs Novavax, Inc.: Strategic Focus on R&D Spending
Research and Development Investment: Viatris Inc. vs Protagonist Therapeutics, Inc.
Viatris Inc. vs Novavax, Inc.: Strategic Focus on R&D Spending
Who Prioritizes Innovation? R&D Spending Compared for Sarepta Therapeutics, Inc. and Protagonist Therapeutics, Inc.
Exelixis, Inc. vs Protagonist Therapeutics, Inc.: Strategic Focus on R&D Spending
R&D Spending Showdown: Alpine Immune Sciences, Inc. vs Novavax, Inc.
Comparing Innovation Spending: CRISPR Therapeutics AG and Protagonist Therapeutics, Inc.
Research and Development Expenses Breakdown: Veracyte, Inc. vs Protagonist Therapeutics, Inc.
Research and Development Investment: Protagonist Therapeutics, Inc. vs Evotec SE